How long does it take to lose 5 stone on Mounjaro?

SURMOUNT-1 trial evidence: average body-weight reduction of ~20–21% at tirzepatide 15mg over 72 weeks (approximately 17–18 months).
Starting weight matters: someone at 20 stone needs a smaller percentage reduction to reach 5 stone lost than someone at 18 stone — your individual trajectory will differ from the trial average.
Dose titration takes time: treatment begins at 2.5mg and increases in steps; most people do not reach their maintenance dose until several months in, which affects the rate of loss early on.
The trial enrolled adults with obesity and no type 2 diabetes; results for people with diabetes or other conditions may differ, your prescriber can discuss what is realistic for you.

Losing 5 stone (31.75 kg) on Mounjaro is within the range suggested by clinical trial data, though the timeline varies considerably between individuals. In SURMOUNT-1, participants taking tirzepatide 15mg lost an average of around 20–21% of body weight over 72 weeks — for someone starting at roughly 22–23 stone, that arithmetic lands close to 5 stone. Real-world timelines depend on your starting weight, the dose you reach, how your body responds, and the lifestyle changes you make alongside treatment. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate before treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence says about the pace of loss, and what shapes it for you

What the SURMOUNT-1 trial actually showed at 72 weeks

The clearest reference point for 5-stone expectations comes from SURMOUNT-1, published in the New England Journal of Medicine. The trial followed 2,539 adults with obesity over 72 weeks. At the highest dose studied (15mg), average weight reduction reached roughly 20–21%. To put that in stone terms: a person starting at 24 stone and achieving 20% loss would shed just under 5 stone. Someone starting at 20 stone would need closer to 25% (above the average) to cross the same threshold.

That distinction matters. The trial result is an average across a large group. Some participants lost considerably more, others less. Your starting weight sets the baseline from which any percentage is calculated, so two people on identical doses can end up with very different stone totals even if their percentage loss is similar.

72 weeks is around 17 months. Not all of that loss arrives evenly: the rate tends to be faster in the first few months once an effective dose is established, then gradually slows as the body adapts. Knowing this can help you interpret your own progress without losing confidence when the scales move more slowly in month eight than they did in month three.

Why the titration schedule affects your early results

Mounjaro treatment starts at 2.5mg, a dose whose job is to let your system adjust, not to drive significant weight loss. The NHS medicines page for tirzepatide describes the escalation pathway: doses increase, typically every four weeks, through 5mg, 7.5mg, 10mg, 12.5mg and 15mg, guided by the prescriber at each step. Reaching the top of that ladder takes roughly five months at minimum, and many people stabilise at an intermediate dose that suits them better.

This means your first few months on Mounjaro may produce more modest results than the trial's headline figures suggest. The landmark losses tend to accumulate once you are at a stable, effective dose. For people targeting 5 stone, patience across the titration phase is genuinely important rather than a platitude. Comparing your week-eight progress to someone else's month-twelve result is not a fair test.

One practical habit worth building: weigh yourself at the same time of day, on the same day each week, wearing similar clothing. A single weekly data point taken consistently is more informative than daily fluctuations and gives you a cleaner picture of your actual trajectory. It takes under a minute and removes a lot of unnecessary noise.

What else shapes the timeline beyond the dose

Trial conditions are controlled; real life is not. Several factors influence how quickly (or slowly) 5 stone comes off in practice.

Starting weight is the most obvious lever: a higher starting weight means a given percentage reduction produces a larger absolute number on the scales. Metabolic factors, age, activity level and how closely a person maintains a reduced-calorie diet alongside treatment all play a role. The NICE appraisal of tirzepatide (TA1026) recommends reviewing progress at six months: if weight loss is less than 5% of starting weight by that point, the prescriber will discuss whether continuing makes sense. That review is not a penalty, it is a clinical check-in that protects you from prolonged treatment without meaningful benefit.

Digestion also changes on tirzepatide. Gastric emptying slows, which contributes to the feeling of fullness that reduces appetite. For some people, this leads to very consistent appetite suppression from early in treatment; for others the effect builds gradually. If you want to understand how those digestive changes actually work, the page on how digestion changes on Mounjaro covers the mechanism in more detail.

People sometimes ask whether results slow after the first stone or two. Broadly, yes. Weight loss in trials followed a pattern common to most effective interventions: steeper early, then a plateau. The plateau does not mean the medicine has stopped working, it often reflects the body settling at a lower set-point. For someone targeting 5 stone, reaching 3 stone and stalling is not unusual, and if you want a detailed look at what the evidence suggests around that point, the guide on how long it typically takes to lose 3 stone on Mounjaro is worth reading before adjusting your dietary approach or activity with your prescriber.

How to think about 5 stone as a realistic target, and when to get clinical input

Five stone is a substantial goal. For many people it is achievable on Mounjaro given enough time and the right dose, but it is not guaranteed and it is not fast. The trial ran for 72 weeks for a reason. Anyone offering you a shorter, certain timeline is not working from the evidence.

If you are earlier in your journey and wondering how the milestones typically stack up, the guides on losing a stone on Mounjaro and losing 2 stone break down the shorter-range picture in the same evidence-based way. For those whose targets sit beyond 5 stone, the guide on how long it takes to lose 4 stone on Mounjaro is a useful stepping-stone reference, and the 6-stone page looks at what the data suggests at greater starting weights.

If you develop severe, persistent stomach pain (particularly pain that radiates toward your back) seek medical help promptly. Acute pancreatitis is a known, infrequent side effect of GLP-1 medicines; the MHRA highlighted this in a January 2026 Drug Safety Update. It is rare, but it is the kind of symptom that should not be waited out at home.

Treatment decisions, dose adjustments and realistic timeline discussions all belong with a prescriber who knows your full medical picture. If you would like that conversation with a clinical team, you can start your free consultation with nume, a GPhC-registered Independent Prescriber reviews every submission the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions